Chemical Structure : Saracatinib
CAS No.: 379231-04-6
Catalog No.: PC-42475Not For Human Use, Lab Use Only.
Saracatinib (AZD0530) is a potent, highly selective, orally available, dual Src/Abl kinase inhibitor with IC50 of 2.7, 4, 4 and 30 nM for c-Src, Yes, Lck and Abl, respectively.
Packing | Price | Stock | Quantity |
---|---|---|---|
25 mg | $78 | In stock | |
50 mg | $128 | In stock | |
100 mg | $218 | In stock | |
250 mg | $358 | In stock | |
1 g | Get quote |
Bulk size, bulk discount!
E-mail: sales@probechem.com
Tech Support: tech@probechem.com
Saracatinib (AZD0530) is a potent, highly selective, orally available, dual Src/Abl kinase inhibitor with IC50 of 2.7, 4, 4 and 30 nM for c-Src, Yes, Lck and Abl, respectively.
Saracatinib (AZD0530) displays high selectivity over a range of kinases (Csk, VEGFR-2, Flt-4, EGFR, and PDGFR).
Saracatinib (AZD0530) exhibits potent inhibition of tumor growth in a c-Src-transfected 3T3-fibroblast xenograft model in vivo.
M.Wt | 542.0265 | |
Formula | C27H32ClN5O5 | |
Appearance | Solid | |
Storage |
|
|
Solubility |
DMSO: ≥ 32 mg/mL |
|
Chemical Name/SMILES |
4-Quinazolinamine, N-(5-chloro-1,3-benzodioxol-4-yl)-7-[2-(4-methyl-1-piperazinyl)ethoxy]-5-[(tetrahydro-2H-pyran-4-yl)oxy]- |
1. Hennequin LF, et al. J Med Chem. 2006 Nov 2;49(22):6465-88.
2. Herynk MH, et al. Mol Cancer Ther. 2006 Dec;5(12):3023-31.
3. Chang YM, et al. Oncogene. 2008 Oct 23;27(49):6365-75.
4. Gwanmesia PM, et al. BMC Cancer. 2009 Feb 13;9:53.
Copyright © 2022 probechem.com. All Rights Reserved. probechem Copyright